I recall you mentioning intrathecal administration a couple years ago. Is this something Race have kept in mind while developing the new formulation?
Maybe this isn't a relevant question now, but possibly interesting. Unless I misunderstood, your comment back then alluded to bisantrene possibly crossing a leaky BBB without being administered intrathecally. Assuming I read that right, are there different levels of severity in a leaky BBB that would change required dosing? Is it a strategy that is employed with other drugs where a framework could be referenced?
- Forums
- ASX - By Stock
- RAC
- Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-60
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.74 |
Change
0.040(2.35%) |
Mkt cap ! $296.3M |
Open | High | Low | Value | Volume |
$1.74 | $1.82 | $1.72 | $216.7K | 124.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 72 | $1.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.76 | 4141 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 72 | 1.740 |
1 | 11547 | 1.730 |
1 | 877 | 1.710 |
4 | 42956 | 1.700 |
1 | 4450 | 1.690 |
Price($) | Vol. | No. |
---|---|---|
1.760 | 4141 | 2 |
1.800 | 2500 | 1 |
1.810 | 2400 | 1 |
1.820 | 8730 | 1 |
1.830 | 15000 | 1 |
Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |